Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.

To the Editor: Dabigatran etexilate 150 mg twice daily (bid) is more effective than warfarin for prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) with no increase in major bleeding ([1][1]). Dabigatran etexilate 110 mg bid reduces major bleeding compared to